Nasdaq:US$16.56 (+0.33) | HKEX:HK$26.05 (+0.40) | AIM:£2.44 (+0.06)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors